How many patients in atrial fibrillation admitted to an acute medical unit will benefit from oral anticoagulation? Application of the results of the major randomized controlled trials to 141 consecutive, unselected, elderly patients using a decision support computer program

European Journal of Internal Medicine

Volumn 16, Issue 2, 2005, Pages 97-104

  Kellett, John ^a  

^a St Joseph's General Hospital Nenagh   (Ireland)

Author keywords

Atrial fibrillation; Decision analysis model; Oral anticoagulation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; WARFARIN;

AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMPUTER ANALYSIS; COMPUTER PROGRAM; DIABETES MELLITUS; FEMALE; FIRST AID; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; QUALITY ADJUSTED LIFE YEAR; STROKE;

EID: 17144371529     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2004.11.004     Document Type: Article

References (37)

1. M. Sudlow, R. Thomson, B. Thwaites, H. Rodgers, and R.A. Kenny Prevalence of atrial fibrillation and eligibility for anticoagulants in the community Lancet 352 1998 1167 1171
2. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group Lancet 342 1993 1255 1262
3. P. Petersen, G. Boysen, J. Godtfredsen, E.D. Andersen, and B. Andersen Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study Lancet 1 1989 175 178
4. Stroke Prevention in Atrial Fibrillation Investigators Stroke prevention in atrial fibrillation study: final results Circulation 84 1991 527 539
5. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation N Engl J Med 323 1990 1505 1511
6. S.J. Connolly, A. Laupacis, M. Gent, R.S. Roberts, J.A. Cairns, C. Jogner Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 18 1991 349 355
7. M.D. Ezekowitz, S.L. Bridgers, K.E. James, N.H. Carliner, C.L. Colling, and C.C. Gornick Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators N Engl J Med 327 1992 1406 1412
8. Atrial Fibrillation Investigators The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials Arch Intern Med 157 1997 1237 1240
9. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent stroke in patients with patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501
10. J.B. Segal, R.L. McNamara, M.R. Miller, N. Kim, S.N. Goodman, and N.R. Powe Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatlet drugs J Gen Intern Med 15 2000 56 67
11. G.W. Albers, J.E. Dalen, A. Laupacis, W.J. Manning, P. Petersen, and D.E. Singer Antithrombotic therapy in atrial fibrillation Chest 119 2001 194S 206S
12. S.G. Pauker, and M.H. Eckman Finding what you seek: analyzing therapies for nonvalvular atrial fibrillation Ann Intern Med 130 1999 690 691
13. M.H. Eckman, H.J. Levine, D.N. Salem, and S.C. Pauker Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues Chest 114 1998 699S 714S
14. H.R. Middlekauff, W.G. Stevenson, and J.A. Gornbein Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation Arch Intern Med 155 1995 913 920
15. I.G. Naglie, and A.S. Detsky Treatment of chronic nonvalvular atrial fibrillation in the elderly Med Decis Making 12 1992 239 249
16. E. Catherwood, W.D. Fitzpatrick, M.L. Greenberg, P.T. Holzberger, D.J. Malenka, and B.R. Gerling Cost-effectiveness of cardioversion and antiarrhythmic therapy in non-valvular atrial fibrillation Ann Intern Med 130 1999 625 636
17. B.F. Gage, A.B. Cardinalli, G.W. Albers, and D.K. Owens Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation JAMA 274 1995 1839 1845
18. M. Man-Son-Hing, and A. Laupacis Balancing the risks of stroke and upper gastrointestinal tract bleeding for older patients with atrial fibrillation Arch Intern Med 162 2002 541 550
19. D.S.G. Conway, and G.Y.H. Lip Commentary: risk for a major bleed was higher for women than men receiving warfarin in patients with atrial fibrillation ACP J Club 135 2001 112
20. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
21. C.S. Landefeld, and L. Goldman Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy Am J Med 87 1989 144 152
22. R.J. Beyth, L.M. Quinn, and S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 1998 91 99
23. G.Y.H. Lip Thromboprophylaxis for atrial fibrillation Lancet 353 1999 4 6
24. Report on Vital Statistics 1993. Central Statistics Office, Government of Ireland 1997.
25. C.V. Walraven, R.G. Hart, D.E. Singer, A. Laupacis, S. Connolly, and P. Petersen Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis JAMA 288 2002 2441 2448
26. M.E. Charlson, P. Pompei, K.L. Ales, and R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
27. S.K. Inouye, P.N. Peduzzi, J.T. Robison, J.S. Hughes, R.I. Horwitz, and J. Concato Importance of functional measures in predicting mortality among older hospitalized patients JAMA 279 1998 1187 1193
28. R.G. Hart, J.L. Halperin, L.A. Pearce, D.C. Anderson, R.A. Kronmal, R. McBride for the Stroke Prevention in Atrial Fibrillation Investigators Lessons from the stroke prevention in atrial fibrillation trials Ann Intern Med 138 2003 831 838
29. SPAF III Writing Committee for Stroke Prevention in Atrial Fibrillation Investigators Patients with non-valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study JAMA 279 1998 1273 1277
30. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
31. C.V. Walraven, R.G. Hart, G.A. Wells, P. Petersen, P.J. Koudstaal, and A.L. Gullov A clinical prediction rule to identify patients with atrial fibrillation and a low risk of stroke while taking aspirin Arch Intern Med 163 2003 936 943
32. D.L. Disch, J.L. Greenberg, P.T. Holzberger, D.J. Malenka, and J.D. Birkmeyer Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone Ann Intern Med 120 1994 449 457
33. J. Protheroe, T. Fahey, and A.A. Montgomery Effects of patients' preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis BMJ 320 2000 1380 1384
34. F.C. Taylor, H. Cohen, and S. Ebrahim Systemic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation BMJ 322 2001 321 326
35. Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 343 1994 687 691
36. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study Arch Intern Med 147 1987 1561 1564
37. R.L. Sacco, P.A. Wolf, W.B. Kannel, and P.M. McNamara Survival and recurrence following stroke. The Framingham Study Stroke 13 1982 290 295